BG63534B1 - Диалкилетери, съдържащи крайни карбоксилни или тетразолни групи - Google Patents

Диалкилетери, съдържащи крайни карбоксилни или тетразолни групи Download PDF

Info

Publication number: BG63534B1
Authority: BG; Bulgaria
Prior art keywords: compound; compound according; cholesterol; administered; alkyl
Prior art date: 1995-03-24

Application number

BG101993A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG101993A (en

Inventor

Chales BISGAIER

Paul CREGER

Alan SALTIEL

Sherrie Tafuri

Original Assignee

Warner-Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-24

Filing date

1997-10-24

Publication date

2002-04-30

1997-10-24 Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc

1998-05-29 Publication of BG101993A publication Critical patent/BG101993A/xx

2002-04-30 Publication of BG63534B1 publication Critical patent/BG63534B1/bg

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/28—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings
- C07C47/37—Saturated compounds having —CHO groups bound to carbon atoms of rings other than six—membered aromatic rings containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
- C07C59/315—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups containing halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups
- C07C59/353—Saturated compounds containing more than one carboxyl group containing keto groups containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Adhesives Or Adhesive Processes (AREA)
Pigments, Carbon Blacks, Or Wood Stains (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Absorbent Articles And Supports Therefor (AREA)
Dental Preparations (AREA)

BG101993A 1995-03-24 1997-10-24 Диалкилетери, съдържащи крайни карбоксилни или тетразолни групи BG63534B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/409,780 US5648387A (en)	1995-03-24	1995-03-24	Carboxyalkylethers, formulations, and treatment of vascular diseases
PCT/US1996/001639 WO1996030328A1 (en)	1995-03-24	1996-02-05	Terminal carboxy or tetrazole groups containing dialkyl ethers

Publications (2)

Publication Number	Publication Date
BG101993A BG101993A (en)	1998-05-29
BG63534B1 true BG63534B1 (bg)	2002-04-30

Family

ID=23621941

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG101993A BG63534B1 (bg)	1995-03-24	1997-10-24	Диалкилетери, съдържащи крайни карбоксилни или тетразолни групи

Country Status (27)

Country	Link
US (4)	US5648387A (xx)
EP (1)	EP0820428B1 (xx)
JP (1)	JP3885115B2 (xx)
KR (1)	KR100408612B1 (xx)
CN (1)	CN1100747C (xx)
AT (1)	ATE192732T1 (xx)
AU (1)	AU692359B2 (xx)
BG (1)	BG63534B1 (xx)
CA (1)	CA2215233C (xx)
CZ (1)	CZ289556B6 (xx)
DE (1)	DE69608268T2 (xx)
DK (1)	DK0820428T3 (xx)
EE (1)	EE03520B1 (xx)
ES (1)	ES2148733T3 (xx)
FI (1)	FI973713A (xx)
GR (1)	GR3034109T3 (xx)
HK (1)	HK1009438A1 (xx)
HU (1)	HUP9801825A3 (xx)
NO (1)	NO307878B1 (xx)
NZ (1)	NZ302170A (xx)
PL (1)	PL181673B1 (xx)
PT (1)	PT820428E (xx)
RU (1)	RU2191772C2 (xx)
SK (1)	SK282897B6 (xx)
UA (1)	UA46020C2 (xx)
WO (1)	WO1996030328A1 (xx)
ZA (1)	ZA962275B (xx)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL119971A (en) *	1997-01-07	2003-02-12	Yissum Res Dev Co	Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
US6861555B2 (en) *	2000-01-25	2005-03-01	Warner-Lambert Company	Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
NZ503982A (en) *	1997-12-12	2002-03-28	Warner Lambert Co	Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
SI1045691T1 (en) *	1997-12-12	2005-04-30	Warner-Lambert Company Llc	Statin-carboxyalkylether combinations
WO1999030706A1 (en) *	1997-12-12	1999-06-24	Warner-Lambert Company	ANTIHYPERLIPIDEMIC STATIN-LP(a) INHIBITOR COMBINATIONS
US20030105154A1 (en)	2001-10-24	2003-06-05	Bisgaier Charles Larry	Statin-carboxyalkylether combinations
CA2311356C (en) *	1998-01-28	2004-07-13	Warner-Lambert Company	Method for treating alzheimer's disease
JP2002525321A (ja) *	1998-09-30	2002-08-13	ワーナー−ランバート・カンパニー	カテーテルによる血管再生を予防または遅らせる方法
IL145712A0 (en) *	1999-04-01	2002-07-25	Esperion Therapeutics Inc	Ether compounds, compositions, and uses thereof
EP1849760A1 (en) *	1999-04-01	2007-10-31	Esperion Therapeutics Inc.	Ether compounds, compositions, and uses thereof
ES2324281T3 (es)	2000-01-25	2009-08-04	Warner-Lambert Company Llc	Eteres de dicarboxilato de calcio, procedimientos de fabricacion de los mismos.
US20040092574A1 (en) *	2000-02-07	2004-05-13	Bisgaier Charles Larry	Statin-Lp(a) inhibitor combinations
BR0110234A (pt) *	2000-04-26	2003-03-05	Warner Lambert Co	Agentes anti-hipertensivos e uso
HUP0301798A3 (en) *	2000-07-14	2004-03-01	Warner Lambert Co	Treatment of eating disorders using carboxyalkylethers
US7304093B2 (en) *	2000-10-11	2007-12-04	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
US6699910B2 (en)	2000-10-11	2004-03-02	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
BR0114623A (pt) *	2000-10-11	2005-12-13	Esperion Therapeutics Inc	Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
BR0114619A (pt)	2000-10-11	2005-12-13	Esperion Therapeutics Inc	Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas
US20040122091A1 (en) *	2000-10-11	2004-06-24	Esperion Therapeutics, Inc.	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
JP2004529069A (ja)	2000-10-11	2004-09-24	エスペリオンセラピューティクス，インコーポレイテッド	コレステロール管理用のエーテル化合物及び組成物ならびに関連する使用
US20030225123A1 (en) *	2001-03-22	2003-12-04	Auerbach Bruce Jeffrey	Antihypertensive agents and use
US20040072903A1 (en) *	2001-05-08	2004-04-15	Auerbach Bruce Jeffrey	Carboxyalkylether-acat inhibitors combinations
US20040192771A1 (en) *	2001-10-11	2004-09-30	Dasseux Jean-Louis Henri	Ether compounds and compositions for cholesterol management and related uses
US20040204502A1 (en) *	2001-10-11	2004-10-14	Dasseux Jean-Louis Henri	Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) *	2001-10-11	2005-01-27	Dasseux Jean-Louis Henri	Sulfide and disulfide compounds and compositions for cholesterol management and related uses
CA2480415A1 (en) *	2002-04-10	2003-10-23	Esperion Therapeutics, Inc.	Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses
EP1539127A1 (en) *	2002-08-22	2005-06-15	Warner-Lambert Company Llc	Method of treating osteoarthritis
US20040048910A1 (en) *	2002-08-22	2004-03-11	Bove Susan Elizabeth	Method of treating osteoarthritis
WO2004024094A2 (en) *	2002-09-13	2004-03-25	Samford University	Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
WO2004045596A1 (en) *	2002-11-15	2004-06-03	Warner-Lambert Company Llc	Method of lowering crp and reducing systemic inflammation
DK2404890T3 (en)	2003-01-23	2017-10-16	Esperion Therapeutics Inc	Hydroxyl compounds and compositions for controlling cholesterol and related uses
US20040229954A1 (en) *	2003-05-16	2004-11-18	Macdougall Diane Elaine	Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
WO2005002557A1 (en) *	2003-07-03	2005-01-13	Warner-Lambert Company Llc	Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050026979A1 (en) *	2003-07-31	2005-02-03	Maha Ghazzi	Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US7390504B2 (en) *	2003-11-07	2008-06-24	Jj Pharma, Inc.	HDL-boosting combination therapy complexes
US20050192347A1 (en) *	2003-12-23	2005-09-01	Dasseux Jean-Louis H.	Urea and thiourea compounds and compositions for cholesterol management and related uses
WO2005068412A1 (en)	2003-12-24	2005-07-28	Esperion Therapeutics, Inc.	Ketone compounds and compositions for cholesterol management and related uses
WO2005068410A1 (en) *	2003-12-24	2005-07-28	Esperion Therapeutics, Inc.	Ether compounds and compositions for cholesterol management and related uses
JP2008502736A (ja) *	2004-06-09	2008-01-31	アバニール・ファーマシューティカルズ	高脂血症および関連疾患の治療のための複素環式誘導体
WO2005123700A1 (en) *	2004-06-09	2005-12-29	Avanir Pharmaceuticals	Small molecules for treatment of hypercholesterolemia and related diseases
EP1753782A1 (en) *	2004-06-09	2007-02-21	Avanir Pharmaceuticals	Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
WO2006045096A2 (en) *	2004-10-20	2006-04-27	Resverlogix Corp.	Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
US8410109B2 (en) *	2005-07-29	2013-04-02	Resverlogix Corp.	Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2008018877A1 (en) *	2006-08-11	2008-02-14	Ssv Therapeutics, Inc.	Carnitine conjugates as dual prodrugs, methods of production and uses thereof
EP2118074B1 (en)	2007-02-01	2014-01-22	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular diseases
US8481084B2 (en)	2007-05-23	2013-07-09	Amcol International Corporation	Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
US7985727B1 (en)	2007-09-20	2011-07-26	Abbott Cardiovascular Systems Inc.	Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) *	2007-09-20	2011-10-25	Abbott Cardiovascular Systems Inc.	Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en)	2007-09-20	2011-07-26	Abbott Cardiovascular Systems Inc.	Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) *	2007-09-20	2012-01-24	Abbott Cardiovascular Systems Inc.	Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) *	2007-09-20	2015-11-03	Abbott Cardiovascular Systems Inc.	Sustained release of Apo A-I mimetic peptides and methods of treatment
SI2346837T1 (sl)	2008-06-26	2015-05-29	Resverlogix Corporation	Postopki pripravljanja kinazolinonskih derivatov
US8952021B2 (en)	2009-01-08	2015-02-10	Resverlogix Corp.	Compounds for the prevention and treatment of cardiovascular disease
WO2010106436A2 (en)	2009-03-18	2010-09-23	Resverlogix Corp.	Novel anti-inflammatory agents
CA2759241C (en)	2009-04-22	2018-03-27	Resverlogix Corp.	Novel anti-inflammatory agents
NZ599059A (en)	2009-09-03	2014-05-30	Pfizer Vaccines Llc	Pcsk9 vaccine
EP2618824A4 (en)	2010-09-20	2015-05-06	Kareus Therapeutics Sa	METHOD AND COMPOSITIONS FOR TREATING DIABETES AND DYSLIPIDEMIA
NO2629776T3 (xx)	2010-10-18	2018-01-13
PL2658536T3 (pl)	2010-12-27	2017-04-28	Gemphire Therapeutics Inc.	Gemcabene i pochodne do leczenia pancreatitis
EP2680883B1 (en)	2011-03-02	2018-09-05	Pfizer Inc	Pcsk9 vaccine
WO2013064900A1 (en)	2011-11-01	2013-05-10	Resverlogix Corp.	Oral immediate release formulations for substituted quinazolinones
AU2013207423B2 (en)	2012-01-06	2017-10-12	Gemphire Therapeutics Inc.	Methods of reducing risk of cardiovascular disease
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Cyclic amines as bromodomain inhibitors
JP2016507496A (ja)	2012-12-21	2016-03-10	ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＣｏｒｐ．	ブロモドメイン阻害剤としての新規複素環式化合物
WO2015123291A1 (en)	2014-02-11	2015-08-20	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Pcsk9 vaccine and methods of using the same
MX2016014306A (es)	2014-05-02	2017-06-12	Cerenis Therapeutics Holding Sa	Marcadores para terapia con lipoproteinas de alta densidad (hdl).
CN111704543A (zh) *	2014-11-14	2020-09-25	燿石治疗公司	用于制备α,ω-二羧酸封端的二烷醚的方法和中间体
CN107530307A (zh)	2015-03-13	2018-01-02	艾斯柏伦治疗公司	包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
JO3789B1 (ar)	2015-03-13	2021-01-31	Resverlogix Corp	التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
MA41793A (fr)	2015-03-16	2018-01-23	Esperion Therapeutics Inc	Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
EP3370703A4 (en)	2015-11-06	2019-06-19	Gemphire Therapeutics Inc.	GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
WO2018165120A1 (en) *	2017-03-06	2018-09-13	Gemphire Therapeutics Inc.	Effect of carboxyalkylethers on obesity symptoms and lipodystropy
JP2020516622A (ja) *	2017-04-18	2020-06-11	ジェムフィアーセラピューティクスインコーポレイテッド	ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
WO2020257573A1 (en)	2019-06-21	2020-12-24	Esperion Therapeutics, Inc.	Salt forms of bempedoic acid and methods for using the same
WO2021021563A1 (en)	2019-07-26	2021-02-04	Espervita Therapeutics, Inc.	Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US20230248678A1 (en)	2020-06-24	2023-08-10	NeuroBo Pharmaceulicals, Inc.	Gemcabene for treating inflammation
WO2022159808A2 (en)	2021-01-25	2022-07-28	Espervita Therapeutics, Inc.	Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
WO2022159811A1 (en)	2021-01-25	2022-07-28	Espervita Therapeutics, Inc.	Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2466419A (en) *	1948-02-07	1949-04-05	Eastman Kodak Co	beta, beta'-oxydipropionic acids and process of preparation
US3320079A (en) *	1960-07-11	1967-05-16	Eastman Kodak Co	Ether-acid polyester composition
US3431298A (en) *	1965-01-05	1969-03-04	Asahi Chemical Ind	Process for the preparation of oxadicarboxylic acids
US3674836A (en) *	1968-05-21	1972-07-04	Parke Davis & Co	2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US3930024A (en) *	1969-09-02	1975-12-30	Parke Davis & Co	Pharmaceutical compositions and methods
BE755997A (fr) *	1969-09-11	1971-03-10	Bp Chem Int Ltd	Production d'acides dicarboxyliques
US3742068A (en) *	1970-04-17	1973-06-26	G Moersch	Ethers of 2,2,9,9-tetramethyl-1,10-decanediol
IT1168389B (it) *	1981-05-06	1987-05-20	Alfa Farmaceutici Spa	Derivati di alcandioli con attivita' ipolipidemizzante,metodi per la loro preparazione e composizioni farmaceutiche che li contengono
DE3423166A1 (de) *	1984-06-22	1986-01-02	Epis S.A., Zug	Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
IL84953A (en) *	1987-12-28	1992-01-15	Bromine Compounds Ltd	3,3'-oxy-bis((2,2'-di(bromomethyl)propanoic acid)derivatives,processes for their preparation and their use as flame retardant agents
DE3814498A1 (de) *	1988-04-29	1989-11-09	Basf Ag	Verfahren zur herstellung von hydroxicarbonsaeureestern
US5395917A (en) *	1993-05-21	1995-03-07	E. I. Du Pont De Nemours And Company	Polyimides from 4-(3-aminophenoxy)benzoic acid

1995
- 1995-03-24 US US08/409,780 patent/US5648387A/en not_active Expired - Lifetime
1996
- 1996-02-05 EP EP96903794A patent/EP0820428B1/en not_active Expired - Lifetime
- 1996-02-05 PT PT96903794T patent/PT820428E/pt unknown
- 1996-02-05 CN CN96193500A patent/CN1100747C/zh not_active Expired - Fee Related
- 1996-02-05 SK SK1286-97A patent/SK282897B6/sk unknown
- 1996-02-05 HU HU9801825A patent/HUP9801825A3/hu unknown
- 1996-02-05 KR KR1019970706637A patent/KR100408612B1/ko not_active IP Right Cessation
- 1996-02-05 CA CA002215233A patent/CA2215233C/en not_active Expired - Fee Related
- 1996-02-05 CZ CZ19972922A patent/CZ289556B6/cs not_active IP Right Cessation
- 1996-02-05 RU RU97118420/04A patent/RU2191772C2/ru not_active IP Right Cessation
- 1996-02-05 AT AT96903794T patent/ATE192732T1/de not_active IP Right Cessation
- 1996-02-05 UA UA97105209A patent/UA46020C2/uk unknown
- 1996-02-05 WO PCT/US1996/001639 patent/WO1996030328A1/en active IP Right Grant
- 1996-02-05 PL PL96322407A patent/PL181673B1/pl not_active IP Right Cessation
- 1996-02-05 ES ES96903794T patent/ES2148733T3/es not_active Expired - Lifetime
- 1996-02-05 AU AU47768/96A patent/AU692359B2/en not_active Ceased
- 1996-02-05 NZ NZ302170A patent/NZ302170A/en unknown
- 1996-02-05 JP JP52934296A patent/JP3885115B2/ja not_active Expired - Lifetime
- 1996-02-05 DK DK96903794T patent/DK0820428T3/da active
- 1996-02-05 EE EE9700375A patent/EE03520B1/xx not_active IP Right Cessation
- 1996-02-05 DE DE69608268T patent/DE69608268T2/de not_active Expired - Lifetime
- 1996-03-20 ZA ZA962275A patent/ZA962275B/xx unknown
1997
- 1997-02-25 US US08/806,580 patent/US5783600A/en not_active Expired - Lifetime
- 1997-02-25 US US08/805,533 patent/US5750569A/en not_active Expired - Lifetime
- 1997-02-25 US US08/806,582 patent/US5756544A/en not_active Expired - Lifetime
- 1997-09-17 FI FI973713A patent/FI973713A/fi not_active IP Right Cessation
- 1997-09-23 NO NO974397A patent/NO307878B1/no not_active IP Right Cessation
- 1997-10-24 BG BG101993A patent/BG63534B1/bg unknown
1998
- 1998-09-04 HK HK98110440A patent/HK1009438A1/xx not_active IP Right Cessation
2000
- 2000-08-02 GR GR20000401806T patent/GR3034109T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU4776896A (en)	1996-10-16
EP0820428B1 (en)	2000-05-10
ATE192732T1 (de)	2000-05-15
CZ292297A3 (cs)	1998-10-14
US5783600A (en)	1998-07-21
NZ302170A (en)	1999-04-29
JP3885115B2 (ja)	2007-02-21
UA46020C2 (uk)	2002-05-15
US5756544A (en)	1998-05-26
HUP9801825A2 (hu)	1998-12-28
NO974397D0 (no)	1997-09-23
HUP9801825A3 (en)	2001-01-29
WO1996030328A1 (en)	1996-10-03
DK0820428T3 (da)	2000-08-28
KR19980703233A (ko)	1998-10-15
CZ289556B6 (cs)	2002-02-13
PL322407A1 (en)	1998-01-19
CA2215233C (en)	2006-07-11
DE69608268T2 (de)	2000-11-09
ZA962275B (en)	1996-11-27
US5750569A (en)	1998-05-12
EP0820428A1 (en)	1998-01-28
RU2191772C2 (ru)	2002-10-27
PL181673B1 (pl)	2001-08-31
SK128697A3 (en)	1999-02-11
GR3034109T3 (en)	2000-11-30
HK1009438A1 (en)	1999-09-10
BG101993A (en)	1998-05-29
PT820428E (pt)	2000-09-29
EE9700375A (et)	1998-06-15
JPH11502532A (ja)	1999-03-02
KR100408612B1 (ko)	2004-03-26
NO974397L (no)	1997-11-20
CA2215233A1 (en)	1996-10-03
CN1100747C (zh)	2003-02-05
ES2148733T3 (es)	2000-10-16
FI973713A0 (fi)	1997-09-17
SK282897B6 (sk)	2003-01-09
US5648387A (en)	1997-07-15
DE69608268D1 (de)	2000-06-15
EE03520B1 (et)	2001-10-15
NO307878B1 (no)	2000-06-13
FI973713A (fi)	1997-09-24
AU692359B2 (en)	1998-06-04
MX9707198A (es)	1997-11-29
CN1182415A (zh)	1998-05-20

Publication	Publication Date	Title
BG63534B1 (bg)	2002-04-30	Диалкилетери, съдържащи крайни карбоксилни или тетразолни групи
EP3520793A2 (en)	2019-08-07	Substances and compostions for use in methods of inhibiting muscle atrophy
CN103889219A (zh)	2014-06-25	包含C16:1n7-棕榈油酸酯的组合物和方法
US7645772B2 (en)	2010-01-12	Treatment of metabolic disorders
IL171638A (en)	2011-06-30	Acids and esters (alkyl-oxy-phenyl) -2-oxo-carboxyls and drugs containing them for the treatment of metabolic disorders
AU1797700A (en)	2000-07-03	Novel ligands of nuclear receptor
DE69228813T2 (de)	1999-08-05	Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen
US6509480B2 (en)	2003-01-21	Glucose and lipid lowering compounds
KR20150002685A (ko)	2015-01-07	동맥경화성 혈관 질환을 치료하기 위한 방법 및 조성물
AU761878B2 (en)	2003-06-12	Glucose and lipid lowering compounds
Moolenaar et al.	2007	Calcium in the action of growth factors
MXPA97007198A (en)	1998-07-03	Eteres dialquilo containing groups with terminal carboxi or tetraz
NZ334611A (en)	2005-03-24	Use of dialkyl ether derivatives in treatment of diseases
Stewart et al.	1964	Antimetabolites of Mevalonic Acid. II. Inhibition of Ergosterol Synthesis in Yeast
SU1068035A3 (ru)	1984-01-15	Способ получени полизамещенных эфиров 4-алкиламинобензойной кислоты
WO1998042350A1 (en)	1998-10-01	Cholesterol lowering pharmaceutical composition
KR20130026399A (ko)	2013-03-13	세포내 대사 촉진용 조성물, 그 조성물을 함유하는 당대사 또는 지질 대사 질환의 예방 및/또는 치료용 의약 제제, 기능성 식품 및 건강식품
KR20130056467A (ko)	2013-05-30	식용 꾀꼬리버섯에서 분리된 신규 아세틸렌산 유도체 및 이의 용도